AGG repeat expansion and aggregation of BIN1 in multiple system atrophy.
Tool / method
AGG repeat expansion in the first intron of BIN1, detected by long-read sequencing, associated with aggregation of the BIN1 protein in glial cytoplasmic inclusions.
Summary
Multiple system atrophy is a fatal, sporadic alpha-synucleinopathy characterised by glial cytoplasmic inclusions in oligodendrocytes, with no causative gene identified to date. Whole-genome sequencing of a patient with familial multiple system atrophy revealed an AGG repeat expansion in the first intron of BIN1, identified by long-read sequencing. Screening for this expansion covered 224 clinically diagnosed patients, 67 pathologically confirmed patients, 574 blood controls and 65 brain controls: expansions exceeding 80 repeats were more frequent in the pathological group than in brain controls (13.4% vs 0%, P = 0.003), with no significant difference in the clinical group compared with blood controls (4.5% vs 2.4%; odds ratio 1.87; 95% CI 0.8-4.5; P = 0.16). Neuropathology showed BIN1-positive glial cytoplasmic inclusions more frequently in expansion carriers, and immunoblotting showed increased insoluble BIN1 in affected brains irrespective of repeat status.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
The divergence between the two cohorts is the central point: the signal appears only in the pathologically confirmed group, which argues as much for heterogeneity of the clinical diagnosis of multiple system atrophy as for a true effect — and rules out any diagnostic use of this expansion for now. The increase in insoluble BIN1 irrespective of repeat status further suggests that aggregation lies downstream of a more general mechanism, of which the expansion would be only one entry point. The bioinformatic interest lies elsewhere: this intronic expansion was beyond the reach of short-read sequencing, a reminder that an already sequenced genome deserves a long-read re-read when no cause is found.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 2/3 · Evidence strength: 2/3 · Novelty: 2/2 · Sample size: 0/1 · Publication status: 1/1 → Total: 7/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime